Starpharma has signed a second, expanded agreement with AstraZeneca in the field of cancer medicine using Starpharma’s proprietary DEP dendrimer drug delivery technology.
The agreement follows on from an evaluation by AstraZeneca, which is capped at $81 billion, which began in September 2012 of Starpharma’s delivery technology, and will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.
AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Partnering Agreements with AstraZeneca 2009-2014
Report: Practical Guide to Finding Partners
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity